(INVO) – Globe Newswire
-
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
-
NAYA Biosciences To Acquire Clinical Stage Gene Therapy ProgramĀ for Leber's Hereditary Optic Neuropathy (LHON)
-
Moore Kuehn Encourages INVO, ESMT, HES, and TGH Investors to Contact Law Firm
Back to INVO Stock Lookup